No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
J.P. Morgan Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating
Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.
Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $22
Lexeo Therapeutics Analyst Ratings
Express News | Lexeo Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $22 From $25